KRT7 Antibodies

Keratin, type II cytoskeletal 7 (KRT7)

Blocks interferon-dependent interphase and stimulates DNA synthesis in cells. Involved in the translational regulation of the human papillomavirus type 16 E7 mRNA (HPV16 E7).

.

Gene Information

Human
Gene Name:	KRT7
Uniprot:	P08729
Entrez:	3855

Family

Belongs to:
intermediate filament family

Alternative Names

CK7; CK-7; cytokeratin 7; cytokeratin-7; K2C7; K7keratin, 55K type II cytoskeletal; keratin 7; keratin, type II cytoskeletal 7; keratin-7; MGC129731; MGC3625; sarcolectin; SCLkeratin, simple epithelial type I, K7; type II mesothelial keratin K7; Type-II keratin Kb7

Molecular Weight

Mass (kDA):
51.386 kDA

Genomic Context

Human
Location:	12q13.13
Sequence:	12; NC_000012.12 (52233243..52252667)

Tissue Specificity

Expressed in cultured epidermal, bronchial and mesothelial cells but absent in colon, ectocervix and liver. Observed throughout the glandular cells in the junction between stomach and esophagus but is absent in the esophagus.

Subcellular Localizations

Cytoplasm.

Diseases

• Neoplasms
• Carcinoma
• Adenocarcinoma
• Malignant Neoplasms
• Neoplasm Metastasis
• Malignant Paraganglionic Neoplasm
• Lung Neoplasms
• Ovarian Neoplasm
• Metaplasia
• Mucinous Adenocarcinoma
• Kidney Neoplasm
• Carcinoma, Transitional Cell

• Liver Neoplasms
• Renal Cell Carcinoma
• Colonic Neoplasms
• Cell Invasion
• Mammary Neoplasms
• Colorectal Neoplasms
• Bladder Neoplasm

Interacting Proteins

• EIF3A

Pathways

• Localization
• Regeneration
• Pathogenesis
• Cell Proliferation
• Cell Adhesion
• Mismatch Repair
• Translation
• Cell Cycle
• Cell Differentiation
• Transdifferentiation
• Dedifferentiation
• Keratinization

• Cell Activation
• Cell Motility
• Liver Regeneration
• Secretion
• Transport
• Cell Migration
• Vasculogenesis

PTMs

• Methylation

• Glycosylation

• Cleavage

Research Areas

• Cell Biology
• Cellular Markers

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/KRT7

Boster Bio Anti-Cytokeratin Peptide 7 (KRT7) Marker

This article will be about the BosterBio Anti–Cytokeratin Proeptide 7 Marker (KRT7Marker). We will also discuss safety and specificity for the Boster Bio KRT7 marker. This article is for all scientists. For more information, please see the entire article. If you have questions, feel free to contact us.

Boster Bio Anti-Cytokeratin Peptide 7 KRT7 Marker

Boster Bio Anti Cytoker peptide 7 (KRT7) marker is a monoclonal anti-cytoker antibody that reacts to Human CK7 protein. The antibody is sold at $125 per kilogram and is compatible to other boster chemicals. To obtain the best results possible for your assays, this antibody is titrated. Its purity is greater than 90% with a filter size of 0.2 um and is stored at -20degC for up to six months.

This antibody detects cysteine 7, a protein commonly found in dysplastic colonic lesions. When used in conjunction with H&E morphology, it can be used as a diagnostic tool for epithelial neoplasms. This antibody is highly specific and has a sensitivity of 98.6%.

This peptide is an intermediate fibril protein (IFP), with a 55 kDa. It does not cross-react with other intermediate filament proteins. It is present in a variety of epithelia, including the ovary, pancreatic, bile, gallbladed, and urothelium. CK7 is a commonly used diagnostic marker in ovarian carcinoma.

Applications

The KRT7 gene may be used to detect stem cell mutations in various types and types of cancer. This marker is rare in normal gastric tissues. However, studies have shown that it can be detected in cancer cells in several other tissue types. KRT7 is associated with many genes that regulate apoptosis. This includes MUC5AC. GAPDH. and CD44. These markers can be useful in many research areas.

ROC curves analysis showed that KRT7, hTERT, SVV markers had the best threshold values. These thresholds were compared with urinary cytology and urine cell cytology sensitivity. The urine biomarkers had a significantly higher sensitivity than the former two and were also more sensitive. These markers, despite being low in sensitivity for urinary cytology are useful for follow up after diagnosis of low grade TCC.

Specificity

One of the most crucial features of the kidneys is the presence or absence of a KRT7 gene marker. This marker is highly expressed in many types of human cancers. It has been linked with an increased risk for cancer recurrence, and death. This gene may be associated with an increased risk of developing kidney cancer. Therefore, it is worth identifying the presence of the gene. This genetic marker was also used to identify potential therapeutic targets in treating cancer.

Urinary levels of the SVV, KRT7, and hTERT have been used for the detection of bladder cancer. These markers have higher sensitivities compared to cytology or other conventional methods. These three markers offer a powerful assay with the potential to improve clinical practice. Despite their limitations however, they may still not be affordable and accessible to all patients. However, when used together, they can be a powerful tool to detect bladder cancer.

ROC curves could be used to evaluate molecular distinction between positive and unfavorable results. The area under curves was significantly larger then the reference line. The optimal cutoff points were chosen to have the highest combination of sensitivity and specificity as well as larger increases in likelihood ratios. KRT7's cutoff values were chosen. It is important not to use KRT7's accuracy for determining the presence of cancer.

KRT7 was the most accurate marker of all three combinations. KRT7 and hTERT gave the highest overall accuracy. These markers did not differ in sensitivity based on sex or history of bladder cancer. They were also not affected based on tumor stage or burden. Moreover, urine cytology performed better than hTERT or KRT7. You can use either KRT7, hTERT, or both to test for cancer.

Safety

Although there has been some controversy about the safety and efficacy of the KRT7 marker it is currently recognized as a reliable diagnostic test in solid epithelial tumors. Moreover, it has also been associated with a positive prognostic value. Further research is needed to identify the exact mechanism and therapeutic role of KRT7. Here's an overview of the potential clinical applications and markers.

A study of 143 patients with advanced breast cancer found that E-CADH and KRT7 levels were associated with higher risk of RD. Combining both markers improved prognosis. Patients with low KRT7 expression had significantly lower PFS and OS. Further analysis revealed that both markers are independent predictors of stage or RD. In the COEUR study, the KRT7 level was predictive of RD and BRCA mutation status.

KRT7 can be found in several cancers. It plays a low prognostic role for pancreatic and gastric cancer. KRT7 overexpression is associated with poorer outcomes in gastric cancer patients than those with pancreatic cancer or esophageal-squamous cell carcinoma. The KRT7/KRT19 subtype is associated to a better prognosis in clear cell renal cell carcinoma as well as papillary kidney cell carcinoma.

The CAF-conditioned medium was used in the study to determine the expression levels KRT7 in PAAD. It was also associated to TP53 mutations, poor prognosis, and other factors. Furthermore, Cox regression analysis showed that overexpression of KRT7 was an independent risk factor for poor survival in PAAD. Interestingly, the expression of KRT7 was associated with the infiltration of immune cells into tumor tissues. GSEA further suggested that KRT7 was associated with regulation of the p53 pathway.

CAF-CM not only evaluates the safety of KRT7, but also measures E-Cadherin (KRT20 and E-Cadherin). The KRT7 marker might be useful in clinical trials for patients with cancer. Despite its limited benefits, safety concerns remain about the CAFCM. It is important to note that the KRT7 marker is a promising diagnostic test for cancer patients.